Align Technology, Inc.
ALGN Healthcare Medical Instruments & Supplies
Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024.
- Revenue
- +1.92%
- EPS
- +143.9%
- Free cash flow
- +8.26%
Quarter to September 2026, against a year earlier
Follow ALGN
Alert me
Align Technology, Inc. (ALGN) EV/EBITDA
As of 5 November 2026, Align Technology, Inc. (ALGN) trades at a EV/EBITDA of 12.6×. Over the past ten years it has ranged from 10.8× (September 2025) to 100× (December 2020); the current reading is higher than 4% of that period. That is below the Medical Instruments & Supplies industry median of 14.9× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 13.1× | (32.50%) |
| FY2024 | 19.4× | (22.32%) |
| FY2023 | 24.9× | 22.75% |
| FY2022 | 20.3× | (56.54%) |
| FY2021 | 46.7× | (45.40%) |
| FY2020 | 85.6× | 149.70% |
| FY2019 | 34.3× | 11.41% |
| FY2018 | 30.8× | (30.29%) |
| FY2017 | 44.1× | 69.54% |
| FY2016 | 26.0× | 13.44% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 11.4× | (16.26%) |
| Jun 2026 | 13.7× | (0.89%) |
| Mar 2026 | 13.8× | 5.50% |
| Dec 2025 | 13.1× | 14.81% |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| SOLV Solventum Corporation compare | 7.6× |
| ALGN Align Technology, Inc. | 12.6× |
| BAX Baxter International Inc. compare | 13.2× |
| ATR AptarGroup, Inc. compare | 13.2× |
| BLCO Bausch + Lomb Corporation compare | 14.6× |
| AVTR Avantor, Inc. compare | 14.7× |
| COO The Cooper Companies, Inc. compare | 15.8× |
| TFX Teleflex Incorporated compare | 35.7× |
| RGEN Repligen Corporation compare | 60.1× |
| Medical Instruments & Supplies industry median | 14.9× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on ALGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement